Assembly Biosciences (ASMB) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Assembly Biosciences (ASMB) has outperformed Rezolute (RZLT) over the past year, losing 12.3% versus a loss of 46.8%. Over five years, RZLT leads with a -30.2% price change compared with -39.9% for ASMB. Assembly Biosciences is the larger company by market cap ($479.1 million vs $471.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | RZLT |
|---|---|---|
| Share price | $23.53 | $4.87 |
| Market cap | $479.08M | $471.04M |
| 1-day change | +3.11% | +4.96% |
| YTD return | -30.81% | +96.61% |
| 1-year return | -12.27% | -46.79% |
| 5-year return | -39.85% | -30.23% |
| P/E ratio (TTM) | 22.63 | — |
| EPS (TTM) | $1.04 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $11.46 |
| 52-week low | $21.80 | $1.07 |
| Distance from 52-week high | -40.75% | -57.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +120.99% | +101.23% |
| Average volume | 279.78K | 1.50M |
| Shares outstanding | 20.36M | 96.72M |
| Employees | 73 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASMB has outperformed RZLT by 34.5 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ASMB vs RZLT FAQ
Which is bigger, Assembly Biosciences or Rezolute?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $479.08M compared with $471.04M for Rezolute (RZLT).
Which stock has performed better over the past year, ASMB or RZLT?
ASMB returned -12.27% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.